Oric Pharmaceuticals Inc Total Liabilities
Oric Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) has total liabilities worth $23.43 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ORIC financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Oric Pharmaceuticals Inc (2017–2025)
Total liabilities of Oric Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how Oric Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Oric Pharmaceuticals Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Oric Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Oric Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jaiprakash Power Ventures Limited
NSE:JPPOWER
|
India | Rs-127.32 Billion |
|
Weibo Corp
NASDAQ:WB
|
USA | $3.08 Billion |
|
PATTIES FOODS
F:PH4
|
Germany | €741.60 Million |
|
Verve Therapeutics Inc
NASDAQ:VERV
|
USA | $140.65 Million |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
USA | $1.93 Billion |
|
Acbel Polytech Inc
TW:6282
|
Taiwan | NT$25.18 Billion |
|
China Harzone Industry Corp Ltd
SHE:300527
|
China | CN¥762.17 Million |
|
Cosmo Pharmaceuticals N.V
F:C43
|
Germany | €123.46 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Oric Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Oric Pharmaceuticals Inc total assets.
Liquidity & Leverage Metrics
Oric Pharmaceuticals Inc Total Liabilities Ratios Explained
Oric Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oric Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oric Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of Oric Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.64 Million | -14.12% |
| 2024-12-31 | $31.02 Million | +1.38% |
| 2023-12-31 | $30.60 Million | +9.25% |
| 2022-12-31 | $28.01 Million | +9.12% |
| 2021-12-31 | $25.67 Million | +178.34% |
| 2020-12-31 | $9.22 Million | +50.69% |
| 2019-12-31 | $6.12 Million | -94.50% |
| 2018-12-31 | $111.16 Million | +2485.72% |
| 2017-12-31 | $4.30 Million | -- |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more